🔗 Share this article

This year's Nobel Prize in Physiology or Medicine was granted for transformative findings that clarify how the body's defense network targets dangerous pathogens while sparing the healthy tissues.

Three esteemed researchers—from Japan Prof. Sakaguchi and American experts Dr. Brunkow and Dr. Ramsdell—received this honor.

Their research identified specialized "sentinels" within the defense system that eliminate malfunctioning defense cells that could attacking the organism.

The findings are now paving the way for new therapies for immune disorders and cancer.

The laureates will share a prize fund valued at 11 million Swedish kronor.

Decisive Findings

"The work has been decisive for comprehending how the body's defenses operates and the reason we do not all suffer from serious self-attack conditions," commented the head of the Nobel Committee.

This trio's studies address a fundamental question: How does the defense system defend us from countless infections while leaving our healthy cells unharmed?

Our immune system uses white blood cells that scan for indicators of disease, even viruses and germs it has never encountered.

Such cells employ detectors—known as recognition units—that are produced by chance in countless variations.

That provides the immune system the ability to fight a wide array of threats, but the unpredictability of the mechanism inevitably produces white blood cells that can attack the host.

Security Guards of the Body

Researchers earlier knew that a portion of these harmful defense cells were eliminated in the thymus—the site where immune cells develop.

The latest Nobel Prize honors the discovery of regulatory T-cells—known as the immune system's "peacekeepers"—which travel through the system to disarm other immune cells that assault the body's own tissues.

It is known that this process fails in self-attack conditions such as juvenile diabetes, multiple sclerosis, and rheumatoid arthritis.

The prize committee stated, "The discoveries have laid the foundation for a new field of investigation and spurred the development of innovative treatments, for instance for tumors and immune disorders."

Regarding malignancies, T-regs prevent the body from fighting the tumor, so studies are focused on lowering their quantity.

In autoimmune diseases, trials are testing boosting regulatory T-cells so the organism is not under attack. A similar method could also be effective in reducing the risks of transplanted organ failure.

Innovative Experiments

Prof Shimon Sakaguchi, from Osaka University, conducted experiments on mice that had their immune gland extracted, leading to self-attack conditions.

He showed that injecting immune cells from other mice could prevent the disease—implying there was a mechanism for blocking immune cells from attacking the body.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Fred Ramsdell, currently at a biotech firm in a California city, were studying an genetic autoimmune disease in mice and humans that led to the identification of a genetic factor vital for the way regulatory T-cells function.

"Their pioneering work has uncovered how the immune system is controlled by T-reg cells, preventing it from mistakenly targeting the body's own tissues," said a prominent biological science expert.

"This work is a remarkable example of how basic physiological study can have broad implications for human health."